ClinicalTrials.gg
CompletedNCT03315780Updated Sep 16, 2019Results posted

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

A Phase 4 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-16.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
54th of 54
12 · median 159
Started
2017
with 1 other
Phase 4
9 of 54
2 open now
Registered
34th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 54th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 4, and was the 34th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes (based on the World Health Organization [WHO] diagnostic criteria) for at least 1 year.
  • Have diet and exercise therapy only (no oral antihyperglycemic medication for at least 3 months prior to screening).
  • Have a fasting blood glucose value of ≥120 and ≤200 milligrams per deciliter (mg/dL) at screening.
  • Have a screening body weight of ≥50 and ≤80 kilograms.

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to dulaglutide, or other glucagon-like peptide-1 (GLP-1) receptor agonists.
  • Have had a cardiovascular disease.
  • Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery.
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease.
  • Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis.
  • Have an estimated (eGFR) \<30 milliliters/minute/1.73 meter squared.
  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Dulaglutide, Placebo

    Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    Placebo, Dulaglutide

    Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.

    Drug: Dulaglutide · Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2189265

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])

    Least square (LS) means of glucose AUC 0-4h change from baseline was calculated using mixed-effects linear model. The model will include treatment, sequence, period, week, and treatment-by-week as fixed effects, baseline as a covariate, and participant as random effect.

    Time frame: Baseline, 4 Weeks

Secondary outcomes

  1. Change From Baseline in Fasting Blood Glucose

    Change from baseline in fasting blood glucose obtained at pre-meal.

    Time frame: Baseline, 4 Weeks

  2. Change From Baseline in Postprandial Blood Glucose

    Change from baseline in postprandial blood glucose at 120 minutes at week 4.

    Time frame: Baseline, 4 Weeks

  3. Change From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

    LS mean of the insulin change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

    Time frame: Baseline, 4 Weeks

  4. Change From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

    LS mean of C-peptide change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

    Time frame: Baseline, 4 Weeks

  5. Change From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

    LS mean of glucagon change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

    Time frame: Baseline, 4 Weeks

  6. Change From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

    LS mean of triglyceride change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

    Time frame: Baseline, 4 Weeks

  7. Number of Participants Who Develop Hypoglycemic Events

    Number of participants who develop hypoglycemic events.

    Time frame: Baseline through 4 weeks

07

Results

Posted Apr 30, 2019

Participant flow

Period 1
Participant flow — Period 1
MilestoneDulaglutide Then PlaceboPlacebo Then Dulaglutide
Started66
Received one dose of study drug66
Completed66
Not completed00
Period 2
Participant flow — Period 2
MilestoneDulaglutide Then PlaceboPlacebo Then Dulaglutide
Started66
Completed66
Not completed00

Outcome measures

PrimaryChange From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])

Least square (LS) means of glucose AUC 0-4h change from baseline was calculated using mixed-effects linear model. The model will include treatment, sequence, period, week, and treatment-by-week as fixed effects, baseline as a covariate, and participant as random effect.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · milligram*hour per deciliter (mg*h/dL)
Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])
milligram*hour per deciliter (mg*h/dL)DulaglutidePlacebo
Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])-238.46 (-293.87 to -183.05)15.56 (-71.27 to 102.39)
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = < 0.0001 · Mean difference (final values): -254.02 · 95% CI -337.76 to -170.28
SecondaryChange From Baseline in Fasting Blood Glucose

Change from baseline in fasting blood glucose obtained at pre-meal.

Time frame:
Baseline, 4 Weeks
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose
milligrams per deciliter (mg/dL)DulaglutidePlacebo
Change From Baseline in Fasting Blood Glucose-39.8 ± 33.3-8.2 ± 21.5
SecondaryChange From Baseline in Postprandial Blood Glucose

Change from baseline in postprandial blood glucose at 120 minutes at week 4.

Time frame:
Baseline, 4 Weeks
Reported as:
Mean · mg/dL
Change From Baseline in Postprandial Blood Glucose
mg/dLDulaglutidePlacebo
Change From Baseline in Postprandial Blood Glucose-67.0 ± 32.113.9 ± 28.7
SecondaryChange From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

LS mean of the insulin change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · insulin units*h/mL (µU*h/mL)
Change From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
insulin units*h/mL (µU*h/mL)DulaglutidePlacebo
Change From Baseline in Insulin Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])25.20 (7.29 to 43.10)-2.27 (-11.39 to 6.85)
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.0100 · Mean difference (final values): 27.46 · 95% CI 8.05 to 46.87
SecondaryChange From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

LS mean of C-peptide change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · nanogram*h/milliliter (ng*h/mL)
Change From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
nanogram*h/milliliter (ng*h/mL)DulaglutidePlacebo
Change From Baseline in C-Peptide Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])3.58 (0.44 to 6.72)-0.14 (-1.24 to 0.96)
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.0263 · Mean difference (final values): 3.72 · 95% CI 0.63 to 6.81
SecondaryChange From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

LS mean of glucagon change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · picomole*h/Liter (pmol*h/L)
Change From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
picomole*h/Liter (pmol*h/L)DulaglutidePlacebo
Change From Baseline in Glucagon Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])-16.39 (-25.69 to -7.09)-7.02 (-12.81 to -1.24)
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.0800 · Mean difference (final values): -9.36 · 95% CI -20.16 to 1.43
SecondaryChange From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])

LS mean of triglyceride change from baseline was analyzed using a mixed-effects linear model. The model includes treatment, sequence, period, week and treat-by-sequence as fixed effects, baseline as a covariate and participant as random effect.

Time frame:
Baseline, 4 Weeks
Reported as:
Least squares mean · mg*h/dL
Change From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])
mg*h/dLDulaglutidePlacebo
Change From Baseline in Triglyceride Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC [0-4h])31.02 (-54.70 to 116.74)46.41 (-76.55 to 169.38)
Statistical analysis
  • Dulaglutide vs Placebo · Mixed Models Analysis · p = 0.7475 · Mean difference (final values): -15.39 · 95% CI -118.35 to 87.57
SecondaryNumber of Participants Who Develop Hypoglycemic Events

Number of participants who develop hypoglycemic events.

Time frame:
Baseline through 4 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Develop Hypoglycemic Events
ParticipantsDulaglutidePlacebo
Number of Participants Who Develop Hypoglycemic Events00

Adverse events

Collected over Baseline up to 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dulaglutide0/12 (0%)0/12 (0%)5/12 (41.7%)
Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventDulaglutidePlacebo
InfluenzaInfections and infestations2/120/12
DiarrhoeaGastrointestinal disorders1/121/12
NauseaGastrointestinal disorders1/120/12
Periodontal diseaseGastrointestinal disorders0/121/12
PericoronitisInfections and infestations0/121/12
PeriodontitisInfections and infestations0/121/12
PharyngitisInfections and infestations1/120/12
Viral upper respiratory tract infectionInfections and infestations0/121/12
Decreased appetiteMetabolism and nutrition disorders1/120/12

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Overall
Mean58.9 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female2
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall
Asian12
Region of Enrollment
Region of Enrollment(Participants)Overall
Japan12
Duration of Diabetes
Duration of Diabetes(years)Overall
Mean8.5 ± 7.7
Screening HbA1c
Screening HbA1c(percentage of HbA1c)Overall
Mean7.9 ± 1.2
Fasting Blood Glucose
Fasting Blood Glucose(milligram per deciliter (mg/dL))Overall
Mean164.67 ± 22.18
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 812-0025, Japan
09

References and documents

Publications

  • Inoue M, Shiramoto M, Oura T, Nasu R, Nakano M, Takeuchi M. Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial. Diabetes Ther. 2019 Jun;10(3):1019-1027. doi: 10.1007/s13300-019-0605-7. Epub 2019 Apr 4. PubMed 30949907 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Feb 2018, 4 months.

Results were first posted in Apr 2019, 1 year 2 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 4 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Oct 20, 2017
StartActual
Oct 28, 2017
Primary completionActual
Feb 28, 2018
CompletionActual
Feb 28, 2018
Results first posted
Apr 30, 2019
Last update
Sep 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03315780
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Oct 28, 2017
Primary completion
Feb 28, 2018
Completion
Feb 28, 2018
Results posted
Apr 30, 2019
Last update
Sep 16, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion